scholarly journals CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus

2021 ◽  
Vol 22 (6) ◽  
pp. 2975
Author(s):  
Erasmia Sampani ◽  
Dimitra-Vasilia Daikidou ◽  
George Lioulios ◽  
Aliki Xochelli ◽  
Zoi Mitsoglou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
T Cells ◽  
T Cell ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Cell Immunity ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: End-stage renal disease (ESRD) is associated with alterations in T-cell immunity, including increased CD28null and reduced regulatory T cells (Tregs). However, whether immune disturbances are due to ESRD or primary disease is not yet clear. As diabetes mellitus is the leading cause of ESRD, we evaluated its impact on the immune profile of ESRD patients. Methods: CD28null, Tregs, and natural killer cells were initially analyzed by flow cytometry in 30 predialysis ESRD patients due to diabetes (DM), 30 non-DM (NDM), and 25 healthy controls. Measurements were repeated after 6 months on hemodialysis (HD) or peritoneal dialysis (CAPD). Results: The percentage of CD4 + CD28null cells, CD8 + CD28null cells, and Tregs showed significant differences in DM, NDM, and controls; mean rank 33.71 vs. 25.68 vs. 18.88, p = 0.006, 37.79 vs. 28.82 vs. 17.08, p = 0.008, and 20.79 vs. 26.12 vs. 41.33, p = 0.001, respectively. DM vs. NDM had increased CD4 + CD28null and CD8 + CD28null cells, 11.5% (1.5%–24%) vs. 4.1% (0–42.3%), p = 0.02 and 61.3% (24%–76%) vs. 43% (5.7%–85%), p = 0.04, respectively. After 6 months on HD but not CAPD, DM showed a significant further increase in CD4 + CD28null cells, from 30 (14–100) to 52.7 (15–203), p = 0.02; and CD8 + CD28null cells, from 137 (56–275) to 266 (103–456), p = 0.01. Conclusions: Diabetes mellitus affects T-cell subtypes even at predialysis stage, though changes become more prominent after commencement on HD.

scholarly journals Association between End-Stage Renal Disease and Incident Diabetes Mellitus—A Nationwide Population-Based Cohort Study

2018 ◽  
Vol 7 (10) ◽  
pp. 343 ◽  
Author(s):  
Pin-Pin Wu ◽  
Chew-Teng Kor ◽  
Ming-Chia Hsieh ◽  
Yao-Peng Hsieh
Keyword(s):  
Diabetes Mellitus ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Lower Risk ◽  
Incident Diabetes ◽  
P Value ◽  
Comparison Cohort ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients

Background: Glucose is one of the constituents in hemodialysates and peritoneal dialysates. How the dialysis associates with the incident diabetes mellitus (DM) remains to be assessed. Methods: The claim data of end-stage renal disease (ESRD) patients who initiated dialysis from and a cohort of matched non-dialysis individuals from 2000 to 2013 were retrieved from the Taiwan National Health Insurance Research Database to examine the risk of incident DM among patients on hemodialysis (HD) and peritoneal dialysis (PD). Predictors of incident DM were determined for HD and PD patients using Fine and Gray models to treat death as a competing event, respectively. Results: A total of 2228 patients on dialysis (2092 HD and 136 PD) and 8912 non-dialysis individuals were the study population. The PD and HD patients had 12 and 97 new-onset of DM (incidence rates of 15.98 and 8.69 per 1000 patient-years, respectively), while the comparison cohort had 869 DM events with the incidence rate of 15.88 per 1000 patient-years. The multivariable-adjusted Cox models of Fine and Gray method showed that the dialysis cohort was associated with an adjusted hazard ratio (HR) of 0.49 (95% CI 0.39–0.61, p value < 0.0001) for incident DM compared with the comparison cohort. The adjusted HR of incident DM was 0.46 (95% CI 0.37–0.58, p value < 0.0001) for HD and 0.84 (95% CI 0.47–1.51, p value = 0.56) for PD. Conclusions: ESRD patients were associated with a lower risk of incident DM. HD was associated with a lower risk of incident DM, whereas PD was not.

Influence of end stage renal disease on CD28 expression and T‐cell immunity

Nephrology ◽  
2020 ◽  
Author(s):  
Erasmia Sampani ◽  
Maria Stangou ◽  
Dimitra‐Vasilia Daikidou ◽  
Vasiliki Nikolaidou ◽  
Despoina Asouchidou ◽  
...  
Keyword(s):  
T Cell ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
T Cell Immunity ◽  
Cell Immunity ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Influence of hemodialysis on circulating CD4lowCD25high regulatory T cells in end-stage renal disease patients

2013 ◽  
Vol 63 (2) ◽  
pp. 99-103 ◽  
Author(s):  
Katarzyna A. Lisowska ◽  
Alicja Dębska-Ślizień ◽  
Aleksandra Jasiulewicz ◽  
Ewa Bryl ◽  
Jacek M. Witkowski
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 133
Author(s):  
Claudia Sommerer ◽  
Anita Schmitt ◽  
Angela Hückelhoven-Krauss ◽  
Thomas Giese ◽  
Thomas Bruckner ◽  
...  
Keyword(s):  
T Cells ◽  
Kidney Transplantation ◽  
T Cell ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Solid Organ ◽  
Peptide Vaccination ◽  
Stage Renal Disease ◽  
End Stage ◽  
Cmv Reactivation

Introduction: Cytomegalovirus (CMV) reactivation occurs in seronegative patients after solid organ transplantation (SOT) particularly from seropositive donors and can be lethal. Generation of CMV-specific T cells helps to prevent CMV reactivation. Therefore, we initiated a clinical phase I CMVpp65 peptide vaccination trial for seronegative end-stage renal disease patients waiting for kidney transplantation. Methods: The highly immunogenic nonamer peptide NLVPMVATV derived from CMV phosphoprotein 65(CMVpp65) in a water-in-oil emulsion (Montanide™) plus imiquimod (Aldara™) as an adjuvant was administered subcutaneously four times biweekly. Clinical course as well as immunological responses were monitored using IFN-γ ELISpot assays and flow cytometry for CMV-specific CD8+ T cells. Results: Peptide vaccination was well tolerated, and no drug-related serious adverse events were detected except for Grade I–II local skin reactions. Five of the 10 patients (50%) mounted any immune response (responders) and 40% of the patients presented CMV-specific CD8+ T cell responses elicited by these prophylactic vaccinations. No responders experienced CMV reactivation in the 18 months post-transplantation, while all non-responders reactivated. Conclusion: CMVpp65 peptide vaccination was safe, well tolerated, and clinically encouraging in seronegative end-stage renal disease patients waiting for kidney transplantation. Further studies with larger patient cohorts are planned.

scholarly journals Natural regulatory T cells from patients with end-stage renal disease can be used for large-scale generation of highly suppressive alloantigen-specific Tregs

2017 ◽  
Vol 91 (5) ◽  
pp. 1203-1213 ◽  
Author(s):  
Nicolle H.R. Litjens ◽  
Karin Boer ◽  
Joke M. Zuijderwijk ◽  
Mariska Klepper ◽  
Annemiek M.A. Peeters ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Large Scale ◽  
Stage Renal Disease ◽  
End Stage

Characterization of Rabbit Antithymocyte Globulins-Induced CD25+ Regulatory T Cells From Cells of Patients With End-Stage Renal Disease

2010 ◽  
Vol 89 (6) ◽  
pp. 655-666 ◽  
Author(s):  
Varsha D. K. D. Sewgobind ◽  
Luc J. W. van der Laan ◽  
Marcia M. L. Kho ◽  
Rens Kraaijeveld ◽  
Sander S. Korevaar ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Propionate supplementation promotes the expansion of peripheral regulatory T-Cells in patients with end-stage renal disease

2020 ◽  
Vol 33 (4) ◽  
pp. 817-827
Author(s):  
Fabian Meyer ◽  
Felix S. Seibert ◽  
Mikalai Nienen ◽  
Marius Welzel ◽  
Daniela Beisser ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

End stage renal disease has an early and continuous detrimental effect on regulatory T cells

Nephrology ◽  
2021 ◽  
Author(s):  
Erasmia Sampani ◽  
Lampis Vagiotas ◽  
Dimitra‐Vasilia Daikidou ◽  
Vasiliki Nikolaidou ◽  
Aliki Xochelli ◽  
...  
Keyword(s):  
T Cells ◽  
Regulatory T Cells ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Detrimental Effect ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document